Article
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Cancer science - 1 Nov 2021
Iwasa Satoru, Muro Kei, Morita Satoshi, Park Young Suk, Nakamura Masato, Kotaka Masahito, Nishina Tomohiro, Matsuoka Hiroshi, Ahn Joong Bae, Lee Keun-Wook, Hong Yong Sang, Han Sae Won, Cho Sang-Hee, Zhang Dong-Sheng, Fang Wei-Jia, Bai Li, Yuan Xiang-Lin, Yuan Ying, Yamada Yasuhide, Sakamoto Junichi, Kim Tae Won
Abstract excerpt
The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer. We evaluated the associations between the UGT1A1 genotype linked to adverse events-caused by irinotecan-and the efficacy and safety...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.